** UBS sees a positive macro backdrop for major European
pharma companies in 2024 with strong cashflows and attractive
valuations
** The broker initiates British GSK GSK.L , French Sanofi
SASY.PA and German Merck MRCG.DE at "buy", citing their
significant scope for a positive 2024 momentum
** It also notes the attractive valuation of Switzeland's
Novartis NOVN.S ("buy"), saying its mid-term EPS growth
above-consensus "justifies a premium"
** The brokerage expects weak U.S. dollar to act as an
earnings drag for Denmark's Novo Nordisk NOVOb.CO ("neutral"),
a high US$ earner, without impacting its underlying growth
** But it starts UK-based AstraZeneca AZN.L with "sell",
flagging concerns about its exposure to U.S. Medicare Part D
reform that may result in price pressures and sales growth
decrease
(Reporting by Anastasiia Kozlova)
((Anastasiia.Kozlova@thomsonreuters.com))